Intrum AB (ITJTY) reports significant leverage improvement and cost reductions, despite facing FX headwinds and a goodwill write-down.

Intrum (OM:INTRUM) remains unprofitable, with its losses growing at an annualized rate of 43.3% over the past five years. While revenue is forecast to grow at just 0.1% per year, well below the Swedish market’s 3.7% annual pace, earnings are expected to turn positive within the next three years. This represents a turnaround rate that exceeds the wider market average. For investors, the key talking points are Intrum’s projected swing to profitability, its low price-to-sales ratio of 0.3x...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.